ANI Pharmaceuticals, Inc. (ANIP), Monday announced the launch of Pimozide Tablets 1 mg and 2 mg, which is the generic version of the reference listed drug (RLD) Orap.
Notably, U.S. annual sales for Pimozide Tablets total approximately $3.1 million, as per the February 2026 moving annual total IQVIA data.
"We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients," commented Nikhil Lalwani, President and Chief Executive Officer of ANI.
In the pre-market hours, ANIP is trading at $82.38, up 1.80 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.